Crick
HomeTrialsGenesDrugs23andMeGraphBlogContact
  • Home
  • Trials
  • Genes
  • Drugs
  • 23andMe
  • Graph
  • Blog
  • Contact
Crick

An open-source clinical intelligence platform. Explore clinical trials, gene networks, and molecular structures using public data sources.

Data Sources

  • ClinicalTrials.gov
  • OpenTargets
  • ClinVar
  • PubChem

Links

  • Contact
  • Privacy

© 2026 Crick. All rights reserved.

Crick is for educational purposes only. Not medical advice.

Results for “MEK Mutation”

Filters

Phase
Early Phase 1
Phase 1
Phase 2
Phase 3
Phase 4
Status
Recruiting
Active, Not Recruiting
Not Yet Recruiting
Completed
Enrolling by Invitation

Showing 20 of 0 results

Testing effectiveness (Phase 2)Ended earlyNCT03705507
What this trial is testing

International Trial of Selumetinib in Combination With Dexamethasone for the Treatment of Acute Lymphoblastic Leukaemia

Who this might be right for
Acute Lymphoblastic LeukemiaAcute Lymphoblastic Leukemia, AdultAcute Lymphoblastic Leukemia, Pediatric+2 more
University of Birmingham 12
Early research (Phase 1)Study completedNCT05441514
What this trial is testing

Enasidenib in Combination With Cobimetinib for the Treatment of Relapsed or Refractory Acute Myeloid Leukemia

Who this might be right for
Recurrent Acute Myeloid LeukemiaRefractory Acute Myeloid Leukemia
City of Hope Medical Center 3
Early research (Phase 1)Looking for participantsNCT06961565
What this trial is testing

PAS-004 in Adults Who Have Neurofibromatosis Type 1 With Plexiform Neurofibromas

Who this might be right for
NF1 MutationNeurofibroma PlexiformNeurofibroma, Plexiform+2 more
Pasithea Therapeutics Corp. 56
Large-scale testing (Phase 3)Active Not RecruitingNCT01933932
What this trial is testing

Assess Efficacy & Safety of Selumetinib in Combination With Docetaxel in Patients Receiving 2nd Line Treatment for v-Ki-ras2 Kirsten Rat Sarcoma Viral Oncogene Homolog (KRAS) Positive NSCLC

Who this might be right for
Locally Advanced or Metastatic Non Small Cell Lung Cancer Stage IIIb - IV
AstraZeneca 510
Testing effectiveness (Phase 2)Active Not RecruitingNCT05195632
What this trial is testing

Phase II Study Investigating the Combination of Encorafenib and Binimetinib in BRAF V600E Mutated Chinese Patients With Metastatic Non-Small Cell Lung Cancer

Who this might be right for
Non-Small Cell Lung Cancer
Pierre Fabre Medicament 63
Early research (Phase 1)Looking for participantsNCT06962254
What this trial is testing

Imatinib and Trametinib for KRAS-mutated Solid Tumor

Who this might be right for
Solid Tumor Cancer
China Medical University Hospital 10
Not applicableStudy completedNCT04039672
What this trial is testing

Interest of Tumor Replicates in Avian Embryo to Model Therapeutic Effects of BRAFi/MEKi in BRAF Mutated Melanoma

Who this might be right for
Melanoma
Hospices Civils de Lyon 10
Early research (Phase 1)UnknownNCT03088176
What this trial is testing

Combining Talimogene Laherparepvec With BRAF and MEK Inhibitors in BRAF Mutated Advanced Melanoma

Who this might be right for
MelanomaBRAF Gene Mutation
West Cancer Center 4
Early research (Phase 1)Ended earlyNCT04965818
What this trial is testing

Phase 1b/2 Study of Futibatinib in Combination With Binimetinib in Patients With Advanced KRAS Mutant Cancer

Who this might be right for
Advanced or Metastatic Solid Tumors Irrespective of Gene AlterationsNon-Small Cell Lung CancerKRAS Gene Mutation
Taiho Oncology, Inc. 38
Testing effectiveness (Phase 2)Study completedNCT05217303
What this trial is testing

HL-085 in NRAS-mutated Advanced Melanoma

Who this might be right for
Melanoma
Shanghai Kechow Pharma, Inc. 100
Early research (Phase 1)Study completedNCT03026517
What this trial is testing

Clinical Trial of Phenformin in Combination With BRAF Inhibitor + MEK Inhibitor for Patients With BRAF-mutated Melanoma

Who this might be right for
Melanoma
Memorial Sloan Kettering Cancer Center 18
Testing effectiveness (Phase 2)Study completedNCT01336634
What this trial is testing

Study of Selective BRAF Kinase Inhibitor Dabrafenib Monotherapy Twice Daily and in Combination With Dabrafenib Twice Daily and Trametinib Once Daily in Combination Therapy in Subjects With BRAF V600E Mutation Positive Metastatic (Stage IV) Non-small Cell Lung Cancer.

Who this might be right for
Cancer
Novartis Pharmaceuticals 177
Testing effectiveness (Phase 2)Ended earlyNCT01978236
What this trial is testing

Dabrafenib/Trametinib, BRAF or BRAF AND MEK Pre-op With BRAF and MEK Post-op, Phase IIB, Melanoma With Brain Mets,Biomarkers and Metabolites

Who this might be right for
Melanoma and Brain Metastases
GlaxoSmithKline 6
Early research (Phase 1)Ended earlyNCT02049801
What this trial is testing

MEK Inhibitor MEK162, Idarubicin, and Cytarabine in Treating Patients With Relapsed or Refractory Acute Myeloid Leukemia

Who this might be right for
Adult Acute Minimally Differentiated Myeloid Leukemia (M0)Adult Acute Monoblastic Leukemia (M5a)Adult Acute Monocytic Leukemia (M5b)+12 more
Bruno C. Medeiros 1
Large-scale testing (Phase 3)Study completedNCT01763164
What this trial is testing

Study Comparing the Efficacy of MEK162 Versus Dacarbazine in Unresectable or Metastatic NRAS Mutation-positive Melanoma

Who this might be right for
Metastatic or Unresectable Cutaneous Melanoma
Pfizer 402
Testing effectiveness (Phase 2)Study completedNCT04620330
What this trial is testing

Avutometinib (VS-6766) + Defactinib in Recurrent KRAS G12V, Other KRAS and BRAF Non-Small Cell Lung Cancer

Who this might be right for
Non Small Cell Lung CancerKRAS Activating Mutation
Verastem, Inc. 90
Large-scale testing (Phase 3)Study completedNCT01584648
What this trial is testing

A Study Comparing Trametinib and Dabrafenib Combination Therapy to Dabrafenib Monotherapy in Subjects With BRAF-mutant Melanoma

Who this might be right for
Melanoma
Novartis Pharmaceuticals 423
Early research (Phase 1)Study completedNCT01363232
What this trial is testing

Safety, Pharmacokinetics and Pharmacodynamics of BKM120 Plus MEK162 in Selected Advanced Solid Tumor Patients

Who this might be right for
Advanced Solid TumorsSelected Solid Tumors
Array Biopharma, now a wholly owned subsidiary of Pfizer 89
Testing effectiveness (Phase 2)Ended earlyNCT04198818
What this trial is testing

Evaluate the Safety, Tolerability and Pharmacokinetics of HH2710 in Patient With Advanced Tumors

Who this might be right for
Advanced TumorsMelanomaNon-Small-Cell Lung Cancer+2 more
Haihe Biopharma Co., Ltd. 37
Testing effectiveness (Phase 2)Not Yet RecruitingNCT07463677
What this trial is testing

Tunlametinib Combination Therapy in KRAS-Mutated Unresectable Locally Advanced or Metastatic Non-Small Cell Lung Cancer

Who this might be right for
Lung Cancer (NSCLC)
Sun Yat-sen University 55
Next Page